Macrocyclic ALK/ROS1 Inhibitor for CNS-Sparing Solid Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for ALK-positive and ROS1-positive solid tumors, particularly in the CNS, suffer from adverse reactions such as dizziness, ataxia, paraesthesia, weight gain, and cognitive changes, and are inadequate against resistance mutations, necessitating the development of CNS-penetrant and TRK-sparing inhibitors.
Innovation Solution
The use of a heteroaromatic macrocyclic ether compound (Compound 1) or its stereoisomers and pharmaceutically acceptable salts for treating solid tumors, including ALK-positive and ROS1-positive cancers, with specific dosing regimens and administration guidelines to minimize adverse effects and target resistant mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TRK inhibitors are used to treat ALK-positive or ROS1-positive solid tumors, then tumor growth is inhibited, but adverse reactions occur particularly in the CNS including dizziness, ataxia, paraesthesia, weight gain and cognitive changes
Solution Approach 1:
The patent extracts and eliminates the harmful TRK inhibition activity from the therapeutic agent. Compound 1 is specifically designed to inhibit ALK and ROS1 kinases while sparing TRK family kinases (TRKA, TRKB, TRKC), thereby removing the source of CNS adverse reactions while maintaining anti-tumor efficacy against ALK-positive and ROS1-positive solid tumors
Solution Approach 2:
The patent applies local quality by achieving selective kinase inhibition. Compound 1 exhibits differential inhibitory activity across the kinase family, strongly inhibiting ALK and ROS1 while showing minimal inhibition of TRK kinases. This selective action profile allows the drug to target tumor-specific kinases without affecting TRK-mediated CNS functions, thereby resolving the contradiction between efficacy and safety
2Reliability
If existing TRK inhibitors are used to treat CNS metastases, then tumor control is achieved, but cognitive changes and other CNS side effects occur
Solution Approach 1:
The patent removes the harmful TRK inhibition component from the drug's mechanism of action. Compound 1 is engineered to lack TRK inhibitory activity while retaining potent ALK and ROS1 inhibition, thereby enabling CNS metastasis control without the cognitive side effects associated with TRK inhibition in the brain
3Adaptability or versatility
If existing ALK inhibitors are used to treat ALK resistance mutations, then treatment options are limited, but inadequate activity against resistance mutations occurs
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Compound 1 to achieve altered kinase selectivity and enhanced potency against resistance mutations. The unique molecular structure of Compound 1 allows it to effectively inhibit ALK kinases with resistance mutations (such as G1202R, F1174L, and others listed in the background) while maintaining selective sparing of TRK kinases, thereby expanding treatment options for resistant cases
Data Source
AI summary
Provided herein are methods of using a heteroaromatic macrocyclic ether compound (e.g., Compound 1), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing solid tumor.